MAPT (Ab-231) Antibody

What is MAPT (Ab-231) Antibody and what epitope does it recognize?

MAPT (Ab-231) Antibody is a rabbit polyclonal antibody that specifically targets the peptide sequence around amino acids 229-233 (V-R-T-P-P) of the human Tau protein . This antibody recognizes the Microtubule-associated protein tau (MAPT), a protein that promotes microtubule assembly and stability, and plays crucial roles in establishing and maintaining neuronal polarity . The antibody targets a specific region of the tau protein that is significant for its normal biological function and can be involved in pathological conditions when altered.

How does MAPT (Ab-231) Antibody differ from phospho-specific Tau antibodies?

The key difference lies in epitope specificity and biological significance:

The phospho-specific antibodies like Anti-Tau (Phospho-T231) specifically recognize tau when phosphorylated at threonine 231, a modification highly associated with pathological conditions . This makes phospho-specific antibodies particularly valuable for investigating disease states, while the non-phospho-specific MAPT (Ab-231) antibody is better suited for detecting total tau protein regardless of its phosphorylation status.

What species reactivity can be expected with MAPT (Ab-231) Antibody?

MAPT (Ab-231) Antibody demonstrates cross-species reactivity with human, mouse, and rat samples . This multi-species reactivity makes it particularly valuable for comparative studies across different model systems. The antibody has been validated through various applications including Western blot analysis of mouse brain tissue extracts , confirming its effectiveness in detecting endogenous tau protein in rodent models commonly used in neuroscience research.

What are the optimal dilution ratios for MAPT (Ab-231) Antibody across different applications?

The optimal dilution ratios vary by application technique:

These recommendations provide starting points for assay optimization. The actual working concentration should be determined empirically by each researcher depending on sample type, detection method, and experimental conditions . When working with brain tissue samples, additional optimization may be necessary due to the complex nature of the tissue and potential cross-reactivity with other proteins.

How should samples be prepared to optimize MAPT (Ab-231) Antibody binding in Western blot applications?

For optimal Western blot results with MAPT (Ab-231) Antibody, sample preparation should follow these methodological steps:

• Extract proteins in a buffer containing protease inhibitors to prevent degradation of the tau protein, which is susceptible to proteolysis .

• If studying phosphorylation states, include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) in the extraction buffer to preserve phosphorylation modifications .

• Use fresh tissue when possible, as tau protein can undergo post-mortem modifications that affect antibody recognition.

• For brain tissue samples, homogenize in cold buffer (4°C) at a ratio of approximately 1:10 (w/v), followed by centrifugation at high speed (>10,000 g) to remove cellular debris .

• Denature samples in loading buffer containing SDS and a reducing agent (β-mercaptoethanol or DTT) at 95°C for 5 minutes to expose the antibody epitope effectively.

• Load 20-50 μg of total protein per lane for adequate detection of tau protein in brain extracts .

Following these procedural steps helps ensure consistent and specific detection of tau protein with minimal background interference.

What positive controls are recommended for validating MAPT (Ab-231) Antibody specificity?

Recommended positive controls for validating MAPT (Ab-231) Antibody specificity include:

• Mouse brain tissue lysate, which has been validated to show specific binding in Western blot applications .

• Human neuroblastoma cell lines (SH-SY5Y) expressing endogenous tau protein.

• Recombinant tau protein (especially isoform 4) for calibration curves and absolute specificity testing.

• Paired samples of control and Alzheimer's disease brain tissue sections for immunohistochemistry validation, which should show differential staining patterns corresponding to tau pathology progression.

• For phosphorylation-dependent studies, samples treated with lambda phosphatase can serve as negative controls when comparing with phospho-specific antibodies .

These positive controls should be run alongside experimental samples to confirm antibody specificity and validate experimental results.

Why might MAPT (Ab-231) Antibody show weak or no signal in Western blots?

Several methodological factors may contribute to weak or absent signals when using MAPT (Ab-231) Antibody in Western blots:

• Protein Degradation: Tau protein is susceptible to proteolytic degradation. Ensure samples are collected, processed, and stored with protease inhibitors at appropriate temperatures (-20°C or -80°C for long-term storage) .

• Inefficient Transfer: Tau proteins, particularly high molecular weight isoforms or aggregated forms, may transfer poorly to membranes. Consider extending transfer time or using specialized buffers for high molecular weight proteins.

• Epitope Masking: Post-translational modifications, especially phosphorylation near the Ab-231 epitope region, might mask the antibody binding site. Enzymatic treatment with phosphatases may restore epitope accessibility in certain cases .

• Antibody Degradation: Repeated freeze-thaw cycles can compromise antibody activity. Store antibody aliquots and avoid more than 5 freeze-thaw cycles .

• Insufficient Antibody Concentration: The standard 1:1,000 dilution might be insufficient for some sample types. Consider testing a more concentrated antibody solution (1:500) for weak signals .

Implementing these methodological refinements should resolve most signal detection issues in Western blot applications.

How can background issues be reduced when using MAPT (Ab-231) Antibody in immunohistochemistry?

To minimize background staining in immunohistochemistry applications with MAPT (Ab-231) Antibody:

• Optimize Blocking: Use 5-10% normal serum from the same species as the secondary antibody for 1-2 hours at room temperature. For particularly challenging samples, consider adding 0.1-0.3% Triton X-100 to improve blocking effectiveness.

• Antibody Dilution Optimization: Begin with the recommended 1:50-1:200 dilution range, but prepare a dilution series to determine optimal signal-to-noise ratio for your specific tissue type .

• Antigen Retrieval Modification: If using heat-induced epitope retrieval, optimize both buffer pH (try citrate buffer pH 6.0 vs. EDTA buffer pH 9.0) and duration (10-30 minutes) to maximize specific signal while minimizing background.

• Endogenous Peroxidase Quenching: For HRP-based detection systems, include a 10-minute treatment with 3% hydrogen peroxide in methanol before primary antibody incubation.

• Secondary Antibody Cross-Adsorption: Use highly cross-adsorbed secondary antibodies to prevent non-specific binding to endogenous immunoglobulins in the tissue.

• Tissue Fixation Considerations: Overfixation can increase background. For formalin-fixed tissues, limit fixation to 24-48 hours and ensure proper buffer exchange during processing.

Implementing these technical refinements should significantly improve signal-to-noise ratio in immunohistochemical applications.

What storage conditions maximize MAPT (Ab-231) Antibody stability and performance?

Proper storage is critical for maintaining MAPT (Ab-231) Antibody functionality over time:

• Aliquot the stock antibody upon receipt to minimize freeze-thaw cycles

• Maintain sterile conditions when handling the antibody

• Avoid exposure to light for fluorophore-conjugated antibodies

• Never store diluted antibody solutions long-term

• Monitor for signs of microbial contamination or precipitation

Following these storage protocols will help maintain antibody performance across multiple experimental sessions.

How does phosphorylation at threonine 231 affect MAPT epitope recognition?

The relationship between phosphorylation at threonine 231 and antibody recognition is complex and methodologically significant:

Phosphorylation at threonine 231 (pT231) is a critical post-translational modification associated with tau pathology in neurodegenerative diseases like Alzheimer's . This modification occurs within the microtubule-binding domain of tau and affects the protein's ability to stabilize microtubules. When using MAPT (Ab-231) Antibody, which targets the region around amino acids 229-233 , phosphorylation at T231 may impact epitope recognition in several ways:

• Epitope Masking: Phosphorylation introduces a negative charge and increases steric hindrance that may partially mask the epitope, potentially reducing binding efficiency of the MAPT (Ab-231) Antibody in hyperphosphorylated tau samples.

• Conformational Changes: pT231 induces conformational changes in the tau protein that may alter accessibility of the 229-233 region, affecting antibody binding kinetics and affinity.

• Disease State Detection: In comparative studies, using both MAPT (Ab-231) and phospho-specific pT231 antibodies provides complementary information about the phosphorylation state of tau in normal versus pathological conditions.

For rigorous experimental design, researchers should consider using complementary antibodies targeting both total tau (like MAPT Ab-231) and phospho-specific epitopes (like pT231) to obtain a complete picture of tau biology in their samples .

Can MAPT (Ab-231) Antibody distinguish between different Tau isoforms?

For experiments requiring isoform-specific detection, researchers should:

• Use high-resolution SDS-PAGE (10-12% acrylamide) with extended running times to separate the different tau isoforms effectively

• Include recombinant tau isoform standards as positive controls

• Consider complementary approaches such as RT-PCR for isoform expression analysis or use of rare isoform-specific antibodies when absolute specificity is required

• For brain tissue analysis, note that isoform expression patterns differ between brain regions and developmental stages, requiring careful experimental design and interpretation

The MAPT (Ab-231) Antibody's ability to detect all isoforms makes it valuable for studying total tau levels, while its limitations in isoform discrimination should be addressed through complementary methodological approaches when isoform-specific information is needed.

What is the relationship between MAPT (Ab-231) Antibody binding and neurodegenerative pathology markers?

The relationship between MAPT (Ab-231) Antibody binding and neurodegenerative pathology markers is complex and contextually dependent:

MAPT (Ab-231) Antibody recognizes an epitope in the tau protein that is present regardless of disease-associated modifications . This characteristic makes it particularly valuable for comparative studies between normal and pathological states. In neurodegenerative diseases like Alzheimer's disease, frontotemporal dementia, and other tauopathies, tau undergoes several pathological changes:

• Hyperphosphorylation: Abnormal phosphorylation at multiple sites, including T231, occurs early in disease progression . While MAPT (Ab-231) binds total tau, phospho-specific antibodies like Anti-Tau (Phospho-T231) provide complementary information about disease-specific modifications.

• Conformational Changes: Pathological tau adopts altered conformations that can affect epitope accessibility. The 229-233 region targeted by MAPT (Ab-231) may have altered exposure in aggregated tau forms.

• Aggregation: As tau forms paired helical filaments and neurofibrillary tangles, the binding pattern of MAPT (Ab-231) may shift from diffuse cytoplasmic to more concentrated in aggregates when used in immunohistochemistry.

• Truncation: Proteolytic cleavage of tau occurs during disease progression, potentially removing the C-terminal region while preserving the Ab-231 epitope, allowing detection of certain tau fragments.

For comprehensive pathological assessment, researchers should employ multiple tau antibodies targeting different epitopes and modifications to characterize the full spectrum of tau pathology. Correlation with other disease markers (amyloid-β, TDP-43, α-synuclein) provides contextual significance to tau findings in neurodegenerative disease research.

How should multiple bands in Western blots using MAPT (Ab-231) Antibody be interpreted?

Multiple bands in Western blots using MAPT (Ab-231) Antibody are common and biologically meaningful. Their interpretation requires careful analysis:

• Isoform Diversity: Human tau exists in six major isoforms ranging from 37-46 kDa depending on the inclusion/exclusion of N-terminal inserts and microtubule-binding repeats . Multiple bands often represent these different isoforms, particularly in brain tissue samples where all isoforms may be expressed.

• Post-translational Modifications: Phosphorylation, glycosylation, acetylation, and other modifications alter tau's electrophoretic mobility. Heavily phosphorylated tau typically migrates slower, appearing as higher molecular weight bands (often seen in Alzheimer's disease samples).

• Proteolytic Processing: Tau undergoes cleavage during both normal turnover and pathological conditions, generating fragments that may retain the Ab-231 epitope. Bands below 37 kDa likely represent these fragments.

• Cross-reactivity Assessment: While the antibody shows high specificity for tau, bands at unexpected molecular weights should be validated with additional antibodies or techniques to rule out non-specific binding .

• Species-Specific Patterns: Mouse and rat tau patterns differ slightly from human patterns due to species-specific isoform expression . Researchers should reference species-appropriate controls.

For rigorous data interpretation, researchers should include recombinant tau standards, dephosphorylated controls (lambda phosphatase-treated samples), and consider parallel blots with phosphorylation-specific antibodies to comprehensively characterize the tau species detected in their experimental system.

What methodological approaches best compare results from MAPT (Ab-231) with phospho-specific antibodies?

To effectively compare results from MAPT (Ab-231) with phospho-specific antibodies such as anti-pT231, researchers should implement these methodological approaches:

• Sequential Blotting: Perform Western blots on identical samples run in parallel, or use mild stripping and reprobing of the same membrane to detect total tau with MAPT (Ab-231) followed by phospho-specific detection. Calculate phosphorylation ratios by normalizing phospho-signal to total tau signal.

• Dual Immunofluorescence: For tissue sections or cultured cells, perform double immunostaining with MAPT (Ab-231) and phospho-specific antibodies using spectrally distinct secondary antibodies. This allows direct visualization of which tau populations are phosphorylated and to what extent.

• Treatment Paradigms: Include conditions that modulate tau phosphorylation, such as:

  • Phosphatase inhibitor treatment (increases phosphorylation)

  • Lambda phosphatase treatment (decreases phosphorylation)

  • Kinase inhibitor treatment (selectively reduces phosphorylation)

• Quantitative Analysis Workflows:

  • For Western blots: Calculate the ratio of phospho-tau to total tau

  • For IHC/IF: Measure colocalization coefficients between total tau and phospho-tau signals

  • For cell models: Track changes in these ratios over time or after treatments

• Controls and Validation:

  • Include both positive controls (AD brain tissue) and negative controls (young control brain tissue)

  • Validate specificity with blocking peptides for both antibodies

  • Consider using tau knockout samples as ultimate negative controls

This integrated approach provides a comprehensive view of both tau expression levels and phosphorylation status, enabling more accurate interpretation of tau biology in experimental and pathological conditions.

How do storage conditions affect long-term experimental reproducibility with MAPT antibodies?

Storage conditions significantly impact experimental reproducibility when working with MAPT antibodies, including MAPT (Ab-231) Antibody:

Long-term studies spanning months or years are particularly vulnerable to antibody variability. To maximize reproducibility:

• Document lot numbers and maintain consistency when possible

• Include internal reference standards in each experiment

• Store antibody performance data (optimal dilutions, signal intensity) to track potential degradation over time

• For critical experiments, validate antibody performance before use with positive controls

• Consider preparing large batches of sample homogenates/lysates and storing them appropriately to reduce sample-preparation variability

Following these systematic approaches to antibody handling and storage will significantly improve experimental reproducibility when working with MAPT antibodies over extended research timelines .

How do results from MAPT (Ab-231) Antibody compare with other tau antibodies in neurodegenerative disease research?

Comparative analysis of MAPT (Ab-231) Antibody with other tau antibodies reveals distinct advantages and limitations for neurodegenerative disease research:

When conducting neurodegenerative disease research, the complementary use of MAPT (Ab-231) with phospho-specific antibodies provides several methodological advantages:

• Phosphorylation Ratio Determination: By normalizing phospho-tau signal to total tau (detected by MAPT Ab-231), researchers can account for variations in total tau expression between samples.

• Disease Progression Monitoring: While MAPT (Ab-231) provides baseline tau levels, phospho-specific antibodies like pT231 track disease-associated changes, allowing for comprehensive disease progression analysis.

• Therapeutic Response Assessment: In drug screening studies targeting tau phosphorylation, MAPT (Ab-231) confirms that reduced phospho-tau signal represents true dephosphorylation rather than degradation of total tau protein.

• Regional Vulnerability Mapping: Combined use allows researchers to determine whether specific brain regions show selective vulnerability based on phosphorylation patterns relative to total tau levels.

This multi-antibody approach provides more comprehensive insights into tau pathology than any single antibody could offer in isolation .

What experimental variables most significantly impact MAPT (Ab-231) Antibody performance?

Multiple experimental variables critically impact MAPT (Ab-231) Antibody performance and should be carefully controlled:

• Sample Preparation Protocol:

  • Fresh vs. frozen tissue (fresh typically yields better results)

  • Fixation method and duration (overfixation can mask epitopes)

  • Extraction buffer composition (detergent type and concentration)

  • Presence of phosphatase inhibitors (critical when comparing to phospho-specific results)

• Detection System Selection:

  • Chromogenic vs. fluorescent detection (sensitivity differences)

  • Signal amplification methods (impacts signal-to-noise ratio)

  • Secondary antibody specificity (affects background levels)

• Incubation Parameters:

  • Temperature (4°C overnight vs. room temperature for shorter periods)

  • Duration (longer incubations may increase sensitivity but also background)

  • Antibody concentration (optimal dilution varies by application)

• Sample Type Considerations:

  • Human vs. rodent tissue (species-specific optimization required)

  • Post-mortem interval (affects protein preservation)

  • Disease state (pathological samples may require modified protocols)

  • Cell type (neurons vs. glial cells have different tau expression profiles)

• Technical Execution:

  • Blocking effectiveness (insufficient blocking increases background)

  • Washing stringency (inadequate washing reduces signal-to-noise ratio)

  • Antibody quality (lot-to-lot variation can occur)

Researchers should systematically optimize these variables for their specific experimental system and maintain strict consistency once optimal conditions are established. Detailed documentation of all experimental conditions facilitates reproducibility and valid cross-study comparisons .

How do tau protein conformational changes impact epitope accessibility for MAPT (Ab-231) Antibody?

Tau protein conformational changes significantly impact epitope accessibility for MAPT (Ab-231) Antibody through several mechanistic pathways:

• Native vs. Pathological Conformations:

  • In its native state, the epitope region is generally accessible in soluble tau

  • During aggregation into paired helical filaments (PHFs), certain epitopes become buried within the core structure while others remain exposed on the filament surface

  • The location of the 229-233 epitope near the proline-rich region means its accessibility may change during the transition from soluble to aggregated states

• Impact of Adjacent Phosphorylation:

  • Phosphorylation at T231, which sits within the Ab-231 epitope region, induces conformational changes that may sterically hinder antibody binding

  • This creates a methodological challenge when comparing samples with different phosphorylation states

• Detection Methodology Considerations:

  • For fixed tissue samples (IHC/IF), antigen retrieval methods can partially restore epitope accessibility

  • In Western blotting, denaturing conditions with SDS disrupts most conformational structures, making the epitope more uniformly accessible

  • For techniques using native conditions (IP, some ELISAs), conformational differences have greater impact on antibody binding

• Experimental Approaches to Address Conformational Variables:

  • Use multiple antibodies targeting different epitopes

  • Include denaturing pretreatment conditions when possible

  • When studying aggregated tau, complement antibody-based detection with conformation-sensitive dyes (Thioflavin-S, FSB)

  • Consider native vs. denaturing conditions when interpreting quantitative differences

These conformational considerations are particularly important when comparing results across different experimental systems or disease states, as they may contribute to apparent discrepancies in tau detection or quantification .